Disclaimer
CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.
Gonadorelin
Also known as: GnRH, LHRH, Factrel, Lutrelef
Gonadorelin is a synthetic form of endogenous gonadotropin-releasing hormone (GnRH), the decapeptide that controls the reproductive hormonal cascade. When administered in a pulsatile fashion, it stimulates LH and FSH release from the pituitary, making it a physiological approach to HPT axis restoration.
Risk Level
Low RiskDifficulty
Intermediate| CAS Number | 33515-09-2 |
| Molecular Formula | C55H75N17O13 |
| Class | Hormone |
| Category | SERMs & AIs |
Mechanism of Action
Gonadorelin binds to GnRH receptors on pituitary gonadotroph cells, stimulating release of LH and FSH. Pulsatile administration mimics natural hypothalamic secretion and maintains receptor sensitivity. Continuous administration, conversely, causes receptor downregulation and suppression of gonadotropins, which is the principle behind GnRH agonist drugs used in prostate cancer.
Dosing Research
Diagnostic use: 100 mcg IV or SC as a single bolus. Pulsatile therapy for hypogonadotropic hypogonadism: 5-20 mcg every 60-120 minutes via pump. Research community protocols: 100-400 mcg SC 1-2 times daily. Very short half-life of 2-4 minutes necessitates frequent or pulsatile dosing for therapeutic effect.
Side Effects & Risks
Generally well-tolerated with pulsatile dosing. Injection site reactions. Headache and nausea uncommon. Continuous (non-pulsatile) dosing will paradoxically suppress gonadotropins. Multi-pregnancy risk when used for ovulation induction. Limited practical utility due to short half-life and need for pulsatile delivery.
Research Studies
Related compounds
Tamoxifen
OtherTamoxifen is a selective estrogen receptor modulator (SERM) that has been the gold standard for breast cancer treatment and prevention since the 1970s. It is one of the most widely used compounds in post-cycle therapy (PCT) for restoring endogenous testosterone production after anabolic steroid use.
Clomiphene Citrate
OtherClomiphene citrate is a SERM originally developed for female ovulation induction and widely adopted in PCT protocols and off-label male hypogonadism treatment. It is a racemic mixture of two geometric isomers, enclomiphene (trans) and zuclomiphene (cis), with differing estrogenic properties.
Anastrozole
OtherAnastrozole is a potent, selective non-steroidal aromatase inhibitor that reduces estradiol levels by approximately 80-85%. It is widely used in breast cancer treatment and is the most commonly employed AI during anabolic steroid cycles to manage estrogen-related side effects.
Letrozole
OtherLetrozole is the most potent of the third-generation aromatase inhibitors, capable of suppressing estradiol by up to 98%. It is FDA-approved for breast cancer and used off-label for ovulation induction in fertility treatment, as well as estrogen control during anabolic steroid cycles.
Disclaimer
CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.